| Objective To investigate the expressions of intercellular adhesion molecule(ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 at levels of transcription, protein translation and also the levels of soluble forms of the two adhesion molecules in patients with acute leukemia.Methods In 61 newly diagnosed acute leukemia patients, The expressions of ICAM-1 and VCAM-1 in bone marrow mononuclear cell (BM-MNC) of patients with acute leukemia were detected by reverse transcription -polymerase chain reaction (RT-PCR) at transcriptional level and western blot at protein translational level. ELISA was also used to detect the levels of soluble ICAM-1 (sICAM-1) and soluble VCAM-1 (sVCAM-1) in serum of patients with acute leukemia.Results1. The expressions of ICAM-1 and VCAM-1 on transcriptional level by RT-PCR are as followed:The expressions of ICAM-1 and VCAM-1 (0.6646±0.0974, 0.6387±0.1145) in newly diagnosed patients with acute leukemia were higher than those in complete remission(CR) group and normal control group (0.5395±0.0898, 0.5243±0.0582; 0.5271±0.0501, 0.5187±0.0542), (P＜0.05). Compared with normal control and CR group, the expression of ICAM-1 in relapse group(0.6862±0.0901) elevated with statistic difference (P＜0.01, P＜0.01). And also the expression of VCAM-1 (0.6725±0.0515) was higher than that in normal control and CR group(P＜0.05, P＜0.05).In newly diagnosed patients with AL, the expression of ICAM-1 in patients who reached CR within two cycles of chemotherapy (0.6359±0.1002) was lower than in patients who didn't achieve CR(0.7439±0.0364)(P＜0.01). And there is statistical difference between 2 groups in the expression of VCAM-1, presented as. 0.6108±0.1193, 0.7107±0.0605, respectively (P＜0.05).The expressions of ICAM-1 and VCAM-1(0.757±0.0319, 0.8946±0.0) in hyperleukocytic group were higher than those in unhyperleukocytic group(0.6566±0.0971, 0.6179±0.0884), (P＜0.05, P＜0.05). The expression of ICAM-1 in patients with extramedullary disease (0.6959±0.0822) was higher than that in patients without extramedullary involvement (0.6259±0.1030) (P＜0.05), while there is no difference in the expression of VCAM-1 between the two groups.2. The expressions of ICAM-1 and VCAM-1 of BM-MNC in patients with AL on protein translational level by western blot.The expressions in translational level of ICAM-1 and VCAM-1 of BM-MNC in newly diagnosed AL were 0.2031±0.1002 and 0.1721±0.034, respectively, which were significantly lower than those in normal control group (0.6482±0.1834, 0.6903±0.2003) and CR group (0.6739±0.2119, 0.7391±0.2453), P＜0.05.3. The results of soluble adhesion molecule, sICAM-1 and sVCAM-1 detected by ELISA, were as followed:The serum concentrations of sICAM-1 and sVCAM-1 in newly diagnosed patients with AL were 549.0±252.2 ng/ml and 2057.2±1310.7ng/ml, respectively, and the concentations were 365.9±216.2 ng/ml and 1269.1±658.2 ng/ml in CR group, 250.3±105.3 ng/ml and 489.6±243.3ng/ml in normal control group, respectively. In soluble form, the expressions of sICAM-1 and sVCAM-1 were higher than those in normal control and CR group, and there is statistical difference.Survival analysis was conducted by kaplan-Meier method, which revealed that the levels of both sICAM-1 and sVCAM-1 had no prognostic value (P＞0.05, P＞0.05).ConclusionsThe expressions of ICAM-1 and VCAM-1 in patients with AL are abnormal at mRNA level, protein level and soluble protein level.The expressions of ICAM-1 and VCAM-1 were correlated with the status of AL. The expressions of ICAM-1 and VCAM-1 in patients who achieved CR can return to normal level, while elevated again after relapse, which suggested ICAM-1 and VCAM-1 may be one of markers involved therapeutic effect and relapse.Patients with various manifestations had different abnormal expressions of ICAM-1 and VCAM-1, which correlate with clinical characteristics. |
PDF Full Text Request